Skip to main navigation Skip to search Skip to main content

The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: Systematic review and meta-analysis

  • Hyasinta Jaka
  • , Jee Ah Rhee
  • , Linda Östlundh
  • , Luke Smart
  • , Robert Peck
  • , Andreas Mueller
  • , Christa Kasang
  • , Stephen E. Mshana
  • Weill Bugando School of Medicine
  • Weil Cornell School of Medicine
  • Cincinnati Children's Hospital Medical Center
  • Cornell University
  • Medical Mission Institute

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

Background: Worldwide Helicobacter pylori (H.pylori) treatment is of great challenge due to increased antibiotic resistance. The burden of H. pylori antibiotic resistance in Africa is high with unclear information regarding the real magnitude. This systematic review and meta-analysis was conducted to investigate the magnitude of H.pylori antibiotic resistance in Africa to gain insight of the extent of the problem among H.pylori naïve treatment patients. Method: The search was performed in the academic databases, Embase, PubMed, Web of Science and Africa Wide Information. ProQuest Dissertation and Theses, Scopus, Ethos, Africa Index Medicus (WHO), BioMed Central Proceedings, BASE, British Library, Open grey, Library of Congress and the New York Academy of Grey Literature Report were additionally searched for grey literature. Published articles from Africa on H.pylori antibiotic resistance between 1986 and June 2017 were systematically reviewed to estimate the H. pylori extent of resistance to macrolides, quinolones, amoxicillin, tetracycline and metronidazole. Results: In 26 articles a total of 2085 isolates were tested for metronidazole, 1530 for amoxicillin, 1277 for tetracycline, 1752 for clarithromycin and 823 for quinolones.The overall pooled proportion of H.pylori resistance to quinolones, clarithromycin, tetracycline, metronidazole and amoxicillin were: (17.4%, 95%CI 12.8 - 21.9), (29.2%, 95%CI:26.7-31.8), (48.7%, 95%CI: 44.5-52.9), (75.8%, 95% CI: 74.1-.77.4) and (72.6%, 95% CI: 68.6-76.6), respectively. The commonest mutation detected were A2143G (49/97) for clarithromycin, RdxA (41/56) for metronidazole and D87I (16/40) for quinolones. Conclusion: Prevalence of metronidazole, clarithromycin, and amoxicillin resistance is high in developing world including Africa. This could impair the first line triple therapy of the H.pylori infection. There is a need of conducting surveillance of H.pylori susceptibility pattern in Africa for dual and triple resistance which can be used for the empirical treatment.

Original languageEnglish
Article number193
JournalBMC Infectious Diseases
Volume18
Issue number1
DOIs
StatePublished - 24 Apr 2018

Keywords

  • Africa
  • Antibiotics resistance
  • Clarithromycin
  • Drug resistance
  • H.Pylori
  • Metronidazole
  • Quinolones

Fingerprint

Dive into the research topics of 'The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: Systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this